ARQT
Arcutis Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.89
+10.65%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$29.41
From 52W high+0.00%
Volume5.78M
Market cap$4.01B
P/E (TTM)144.4x
P/S (TTM)8.6x
Div yield—
Key dataOct 19, 2026
Open
$29.41
From 52W high
+0.00%
Volume
5.78M
Market cap
$4.01B
ValuationView details →
P/E (Fwd)
37.2x
EV/EBITDA
89.4x
P/E (TTM)
144.4x
RSI (14)
73.0
MomentumView details →
1D Return
+10.65%
YTD Return
+9.52%
SummaryUpdated Jun 1, 2026
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a commercial-stage biopharmaceutical company founded in 2016 and headquartered in Westlake Village, California. The company went public in January 2020 and focuses on developing and commercializing innovative treatments for dermatological diseases. Arcutis has successfully transitioned from a clinical-stage company to a commercial enterprise, with its flagship product ZORYVE generating significant revenue growth since its initial launch for plaque psoriasis in 2022.
Similar companies
Latest newsMore news →
Arcutis Biotherapeutics, Inc. shares traded higher on Thursday.4d agoArcutis Biotherapeutics' ZORYVE (roflumilast) cream 0.15% received the 2026 "Best Prescription Skin Solution" Award from Marie Claire magazine.14d agoArcutis Biotherapeutics (ARQT) shares rose 11.2% in the previous trading session on higher-than-average volume.33d ago